18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

a study on Primary Hyperparathyroidism

Summary

Eligibility
for people ages 13 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Thomas Hope, MD
Headshot of Thomas Hope
Thomas Hope

Description

Summary

This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.

Details

PRIMARY OBJECTIVE:

  1. To investigate the performance (accuracy) of 18F-fluorocholine PET in the detection of hyperfunctioning parathyroid glands in surgical patients with biochemically proven primary hyperparathyroidism.

OUTLINE:

Participants will receive a single dose of 18F-Fluorocholine at the time the participant undergoes a single imaging study using 18F-fluorocholine. Study related procedures will end after the study visit. Participants who undergo subsequent parathyroidectomy, will have the results reviewed and compared to the results from the imaging study

Keywords

Hyperparathyroidism, Primary, Adenoma, Parathyroid Neoplasms, Hyperparathyroidism, Primary Hyperparathyroidism, 18F-Fluorocholine, Positron emission tomography (PET), Fluorocholine PET Imaging

Eligibility

You can join if…

Open to people ages 13 years and up

  • Age >= 13 years.
  • Biochemically proven hyperparathyroidism and an indication for surgery.
  • Ability to understand a written informed consent document, and the willingness to sign it.

You CAN'T join if...

  • Current Pregnancy.
  • Patients unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.

Location

  • UCSF accepting new patients
    San Francisco California 94107 United States

Lead Scientist at UCSF

  • Thomas Hope, MD
    Thomas Hope, MD, is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology. He also serves as the Director of Molecular Therapy. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center and as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Thomas Hope
ID
NCT04895631
Phase
Phase 3 Primary Hyperparathyroidism Research Study
Study Type
Interventional
Participants
Expecting 140 study participants
Last Updated
Contact us about this trial